25例晚期及复发子宫内膜癌紫杉醇联合化疗分析

[目的]评价紫杉醇联合化疗治疗晚期、复发子宫内膜癌的近期疗效及毒副作用.[方法]25例Ⅲ、Ⅳ期或复发的子宫内膜癌行紫杉醇 卡铂(或顺铂)化疗,紫杉醇135mg/m2～150mg/m2,卡铂AUC 4～5,或顺铂70mg/m2.[结果]有可测肿瘤或CA125/CA199升高16例,共进行63个疗程化疗,完全缓解37.5%,部分缓解25.0%,总有效率62.5%.完全缓解者无进展期平均5.3个月.无肿瘤监测指标9例,进行29个疗程化疗,中数随诊11.5个月无复发.3、4级白细胞下降40.0%,3级血小板下降11.4%.[结论]紫杉醇 卡铂或顺铂联合化疗对晚期、复发的子宫内膜癌有较好疗效.

An Analysis of Paclitaxel in Patients with Advanced or Recurrent Adenocarcinoma of The Endometrium

To determine the efficacy and toxicity of paclitaxel in advanced or recurrent adenocarcinoma of the endometrium.Twenty-five patients with advanced or recurrent endometrial cancer were treated with pacli-taxel135mg/m 2 or150mg/m 2 over3hours and carboplatin AUC4~5or cisplatin70mg/m 2 .Sixteen cases with measurable disease or elevated received a total of63courses chemotherapy CA125/CA199.The overall response rate was62.5%with complete response37.5%and partial response25.0%.Median progression-free interval in patients of com-plete responses was5.3months.Severe(grade3or4)leukopenia or thrombocytopenia was40.0%and11.4%respec-tively.[Conclusion]This regimen of paclitaxel and carboplatin or cisplatin are active in patients with advanced or re-current adenocarcinoma of the endometrium.